AB=CD
In this case, AB is equal to CD, which is ideal but not always the case..
You can use the magnet and move the AB leg to the CD position to see if it fits. This pattern when bullish, looks like a downtrend and is sometimes found within a larger downtrend, so be safe. The bearish version would begin with AB, or leg 1 to the upside. In the bullish version, the AB leg is downward as is the CD leg with an uptrace at the BC leg. The retracement (up-tracement leg BC)) can be between 38.2% to 78.6% of the A-B leg, however, an ideal pattern has a retracement of 61.8% to 78.6%. The ideal AB=CD pattern is equal in time and price, with point D being an Fibonacci extension between 127%-161.8% of the B-C leg.
The pattern consists of three legs, with two equal legs labelled AB and CD, together they form a zig-zag shape. For this reason it is sometimes called the 'lightning bolt pattern'.
Plenty of resistance overhead.
The market has been tough and it does not seem to be a good idea to hang around too long.
PE Ratio is high at 90.06. Short interest is around 3.78%. Earnings estimated to be July 28.
Possible Stop below D or where you see support.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company’s products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
EPS (FWD)
3.31
PE (FWD)
90.06 ****
Div Rate (FWD)
Yield (FWD)
Short Interest
3.78%
Market Cap
28.37B
Trade at your own risk/No recommendation
You can use the magnet and move the AB leg to the CD position to see if it fits. This pattern when bullish, looks like a downtrend and is sometimes found within a larger downtrend, so be safe. The bearish version would begin with AB, or leg 1 to the upside. In the bullish version, the AB leg is downward as is the CD leg with an uptrace at the BC leg. The retracement (up-tracement leg BC)) can be between 38.2% to 78.6% of the A-B leg, however, an ideal pattern has a retracement of 61.8% to 78.6%. The ideal AB=CD pattern is equal in time and price, with point D being an Fibonacci extension between 127%-161.8% of the B-C leg.
The pattern consists of three legs, with two equal legs labelled AB and CD, together they form a zig-zag shape. For this reason it is sometimes called the 'lightning bolt pattern'.
Plenty of resistance overhead.
The market has been tough and it does not seem to be a good idea to hang around too long.
PE Ratio is high at 90.06. Short interest is around 3.78%. Earnings estimated to be July 28.
Possible Stop below D or where you see support.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company’s products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
EPS (FWD)
3.31
PE (FWD)
90.06 ****
Div Rate (FWD)
Yield (FWD)
Short Interest
3.78%
Market Cap
28.37B
Trade at your own risk/No recommendation
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。